CYP2A6 (Cytochrome P450 Family 2 Subfamily A Member 6)

By linking germline variants to more biologically relevant gene targets and somatic processes, our results align more closely with established epidemiological and environmental risk factors for lung cancer, including a potential genetic explanation for the environmental interaction of caffeine and smoking in LC risk. This highlights the value of integrating 3D genome architecture and tissue-specific expression to refine our understanding of cancer susceptibility.

Finally, in vitro validation experiments using AGS and HGC-27 cell lines confirmed that elevated CYP2A6 expression promotes the progression of GC. This finding indicates that CYP2A6 may be a new biomarker in the therapeutic management of the disease.

P=N/A, N=16, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=50 --> 16 | Trial completion date: Dec 2024 --> Apr 2025

Our study revealed that FHC was strongly associated with the elevated risk of having CRC in Kashmir. The prevalence of genetic factors were also found in this association.

These results together suggest the potential of CYP2A6 as a biomarker and therapeutic target for HCC. Its modulation of the SRC/Wnt/β-Catenin pathway provides a new insight for HCC treatment.

CYP2A6 polymorphisms correlate with S-1 efficacy (OS, PFS) in gastric cancer, suggesting their potential as predictive markers. However, the generalizability of findings is limited by the small number of studies from Eastern countries and variations in chemotherapy regimens and detection methods. Further large-scale studies are needed to confirm these associations.

The chemotherapeutic agent tegafur, a prodrug that prolongs the half-life of fluorouracil (5-FU), exerts antitumor effects against various cancers...Furthermore, administration of tegafur to mice transplanted with 4T1 breast cancer cells during the dark period suppressed increases in tumor size compared to female mice treated during the light period. Our findings reveal a novel relationship between 5-FU prodrugs and circadian clock machinery, potentially influencing antitumor effects, and contributing to the development of time-aware chemotherapy regimens for breast cancer.

P=N/A, N=50, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2023 --> Dec 2024